Focus on Asthma Care

Back to articles

Omalizumab beneficial for children, young adults with allergic asthma

KEY POINT

Adding omalizumab (Xolair—Genentech/Novartis) to guideline-based therapy reduced asthma symptoms and use of inhaled corticosteroids and nearly eliminated seasonal increases in asthma attacks among young people living in inner city environments.

SOURCES

Busse W et al. Randomized trial of omalizumab (Anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364:1005–15.